Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

Rajkumar, S V, Gupta, V, Fonseca, R, Dispenzieri, A, Gonsalves, W I, Larson, D, Ketterling, R P, Lust, J A +2 more·2013·Leukemia
DOI 10.1038/leu.2013.86

Cited by (238)

Items 101–200 of 238

  1. Impact of cell fusion in myeloma marrow microenvironment on tumor progression
    Ziyan Wang, Yuqing Yuan, Liying Zhang, Zhou Min, Dongming Zhou, Yu Sun, Panjun Wang, Songguang Ju, Jun Li, Jinxiang Fu · 2018 · Oncotarget
  2. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma
    Timothy Martin Schmidt, Natalie S. Callander · 2020 · Journal of the National Comprehensive Cancer Network
  3. Treatment of smoldering multiple myeloma
    S. Vincent Rajkumar, Robert A. Kyle · 2013 · Nature Reviews Clinical Oncology
  4. The role of 1q abnormalities in multiple myeloma: Genomic insights, clinical implications, and therapeutic challenges
    Zachary M. Avigan, Constantine S. Mitsiades, Alessandro Laganà · 2024 · Seminars in Hematology
  5. Diagnosis and management of smoldering multiple myeloma: the razor’s edge between clonality and cancer
    Eli Muchtar, Shaji Kunnathu Kumar, Hila Magen, Morie Abraham Gertz · 2017 · Leukemia & lymphoma/Leukemia and lymphoma
  6. Smoldering multiple myeloma – Past, present, and future
    Hashim Mann, Vatsala Katiyar, Cindy Varga, Raymond L. Comenzo · 2021 · Blood Reviews
  7. Baseline serum B‐cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma
    Sean Elliott Bujarski, Marissa‐Skye Goldwater, Bernard Sean S. Regidor, Scott Kristian Jew, David Daniely, Regina A. Swift, Benjamin Eades, Marsiye Emamy‐Sadr, Eric Souther, Mingjie Li et al. · 2021 · European Journal Of Haematology
  8. Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?
    Manisha Bhutani, Ola Landgren, Saad Z. Usmani · 2015 · American Society of Clinical Oncology Educational Book
  9. Asymptomatic Monoclonal Gammopathies
    Claire Bories, Sundar Jagannath · 2014 · Clinical Lymphoma Myeloma & Leukemia
  10. Risk Stratification and Treatment in Smoldering Multiple Myeloma
    Tyler Lussier, Natalie Schoebe, Sabine Mai · 2021 · Cells
  11. The road to cure in multiple myeloma starts with smoldering disease
    Karma Ziad Salem, Irene M. Ghobrial · 2015 · Expert Opinion on Orphan Drugs
  12. Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India
    Perumal Govindasamy, Prabu Pandurangan, Anil Tarigopula, Rama Mani, Chandra R Samuel · 2019 · Asian Pacific Journal of Cancer Prevention
  13. What Is New in the Treatment of Smoldering Multiple Myeloma?
    Niccolò Bolli, Nicola Sgherza, Paola Curci, Rita Rizzi, Vanda Strafella, Mario Delia, Vito Pier Gagliardi, Antonino Neri, Luca Baldini, Francesco Albano et al. · 2021 · Journal of Clinical Medicine
  14. Multiple Myeloma from the Perspective of Pro- and Anti-Oxidative Parameters: Potential for Diagnostic and/or Follow-Up Purposes?
    Ayşe Nilgün Kul, Bahar Ozturk Kurt · 2024 · Journal of Personalized Medicine
  15. Multiple Myeloma: Role of Imaging in Diagnosis, Staging, and Treatment Response Assessment
    Sameh Nassar, Ahmed Taher, Rosario Spear, Felicia Wang, John E. Madewell, Bilal Mujtaba · 2020 · Seminars in Ultrasound CT and MRI
  16. Multiple myeloma in Saudi Arabia: Consensus of the Saudi lymphoma/myeloma group
    Ahmed S. Alaskar, Ahmad S. Alsaeed, Fahad Z. Alsharif, Hani Alhashmi, Mubarak S. AlGhamdi · 2019 · Journal of Applied Hematology
  17. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics
    Srinath Sundararajan, Abhijeet Kumar, Neha Korde, Amit Agarwal · 2016 · Current Hematologic Malignancy Reports
  18. TRIM44, a Novel Prognostic Marker, Supports the Survival of Proteasome-Resistant Multiple Myeloma Cells
    Trung Vu, Yuqin Wang, Annaliese Fowler, Anton Simieou, Nami McCarty · 2024 · Cells
  19. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
    Nelson C. N. Chan, N. P. Chan · 2017 · Methods in molecular biology
  20. Conventional Karyotyping and Fluorescence In Situ Hybridization for Detection of Chromosomal Abnormalities in Multiple Myeloma
    Matthew Crabtree, Jennifer X. Cai, Xin Qing · 2022 · Journal of Hematology
  21. Smoldering Multiple Myeloma: When to Observe and When to Treat?
    María‐Victoria Mateos, Jesús F. San Miguel · 2015 · American Society of Clinical Oncology Educational Book
  22. Bildgebung bei „smoldering“ (asymptomatischem) multiplem Myelom
    Manisha Bhutani, Ola Landgren · 2014 · Der Radiologe
  23. Multiple Myeloma and Related Disorders
    S. Vincent Rajkumar, Angela A. Dispenzieri · 2020 · Elsevier eBooks
  24. Evolution of Multiple Myeloma from a Genomic Perspective
    Maura, Francesco, Samur, Mehmet, Munshi, Nikhil · 2026 · Blood
  25. SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
    Timothy Martin Schmidt, Zhubin J. Gahvari, Natalie S. Callander · 2024 · Clinical Lymphoma Myeloma & Leukemia
  26. Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders
    Salomon Manier, Karma Ziad Salem, David Liu, Irene M. Ghobrial · 2016 · American Society of Clinical Oncology Educational Book
  27. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice
    Federica Cocito, Silvia Mangiacavalli, Virginia Valeria Ferretti, Claudio Salvatore Cartia, Maya Ganzetti, Pietro Benveuti, Alessandra Pompa, Martina Catalano, Elena Fugazza, Benedetta Landini et al. · 2019 · Leukemia & lymphoma/Leukemia and lymphoma
  28. How We Approach Smoldering Multiple Myeloma
    Noopur S Raje, Andrew Jenho Yee · 2020 · Journal of Clinical Oncology
  29. Role of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple Myeloma
    Maciej Dubaj, Karol Bigosiński, Aleksandra Dembowska, Radosław Mlak, Aneta Szudy‐Szczyrek, Teresa J Malecka-Massalska, Iwona Homa‐Mlak · 2024 · Cancers
  30. Cytogenetic Profile in Monoclonal Gammopathy of Undetermined Significance, Smoldering and Symptomatic Multiple Myeloma: A Study of 1087 Patients with Highly Purified Plasma Cells
    Guilin Tang, Yilin Wu, Pei Lin, Gökçe Törüner, Shimin Hu, Shaoying Li, Muzaffar H. Qazilbash, Robert Zygmunt Orlowski, Christine Ye, Jie Xu et al. · 2023 · Cancers
  31. Predicting the Progression from Asymptomatic to Symptomatic Multiple Myeloma and Stage Classification Using Gene Expression Data
    Nestoras Karathanasis, George M. Spyrou · 2025 · Cancers
  32. The success rate of interphase fluorescence in situ hybridization in plasma cell disorders can be improved using unconventional sources of plasma cells
    Vandana Panakkal, Sonia Rana, Shailja Rathore, Anshu Anshu, Anand Balakrishnan, Charanpreet Singh, Aditya Jandial, Man Updesh Singh Sachdeva, Neelam Varma, Deepesh Pravinkumar Lad et al. · 2021 · International Journal of Laboratory Hematology
  33. A Five-Gene Risk Score Model for Predicting the Prognosis of Multiple Myeloma Patients Based on Gene Expression Profiles
    Xiaotong Chen, Lintao Liu, Mengping Chen, Jing Xiang, Yike Wan, Xin Li, Jinxing Jiang, Jian Hou · 2021 · Frontiers in Genetics
  34. Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives
    Igor Valentim Barreto, Caio Bezerra Machado, Davi Benevides Almeida, Flávia Melo Cunha de Pinho Pessoa, Renan Brito Gadelha, Laudreísa da Costa Pantoja, Deivide de Sousa Oliveira, Rodrigo Monteiro Ribeiro, Germison Silva Lopes, Manoel Odorico de Moraes et al. · 2022 · Pharmaceutics
  35. Still high risk? A review of translocation t(14;16) in multiple myeloma
    Hira S. Mian, Martin Kaiser, Rafaël Fonseca · 2024 · American Journal of Hematology
  36. Timing treatment for smoldering myeloma: is earlier better?
    José‐Ángel Hernández‐Rivas, Joaquín Martínez‐López, Juan José Lahuerta · 2019 · Expert Review of Hematology
  37. Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study
    Camille Tessier, Thomas Allard, Jean‐Samuel Boudreault, Rayan Kaedbey, Vincent Éthier, Fléchère Fortin, Michel Pavic · 2021 · Current Oncology
  38. The Road to Treating Smoldering Multiple Myeloma
    Neha Korde, Sham Mailankody, Ola Landgren · 2014 · Clinical Lymphoma Myeloma & Leukemia
  39. Smoldering Multiple Myeloma
    Minjie Gao, Guang Yang, Yuanyuan Kong, Xiaosong Wu, Jumei Shi · 2015 · BioMed Research International
  40. Smoldering multiple myeloma: present position and potential promises
    Nishant Tageja, Elisabet Esteve Manasanch, Neha Korde, Mary Kwok, Sham Mailankody, Manisha Bhutani, Mark J. Roschewski, Ola Landgren · 2013 · European Journal Of Haematology
  41. Controversies in multiple myeloma: Evidence-based update
    Inhye E. Ahn, Sham Mailankody · 2016 · Seminars in Oncology
  42. Diagnosis and Staging of Multiple Myeloma and Related Disorders
    S. Vincent Rajkumar, Rafaël Fonseca, Jesús F. San Miguel · 2017 · Hematologic malignancies
  43. Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society
    Yoshiaki Abe, Kazutaka Sunami, Takeshi Yamashita, Ueda Mikio, Hiroyuki Takamatsu, Kentaro Narita, Hiroki Kobayashi, Akihiro Kitadate, Masami Takeuchi, Kosei Matsue · 2019 · Oncotarget
  44. MyeloDB: a multi-omics resource for multiple myeloma
    Ambuj Kumar, Keerthana Vinod Kumar, Kavita Kundal, Avik Sengupta, Simran Sharma, R Kunjulakshmi, Rahul Kumar · 2024 · Functional & Integrative Genomics
  45. How to Identify and Manage High-Risk Smoldering Multiple Myeloma
    Tarek H. Mouhieddine · 2024 · Current Oncology Reports
  46. Advances in the management of asymptomatic myeloma
    María‐Victoria Mateos · 2014 · Current Opinion in Oncology
  47. Progress in the Management of Smoldering Multiple Myeloma
    Timothy Martin Schmidt, Natalie S. Callander · 2021 · Current Hematologic Malignancy Reports
  48. Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
    Marta Lionetti, Matteo Da Vià, Francesco Albano, Antonino Neri, Niccolò Bolli, Pellegrino Musto · 2021 · Cancers
  49. Glasgow Prognostic Score Serves as a Prognostic Factor of Clinical Outcome in Patients with Newly Diagnosed Multiple Myeloma
    Shuzhen Li, Limei Zhang, Shutong Liu, Zhijian Liang, Weida Wang, Yun Wang, Liang Yang · 2025 · Journal of Inflammation Research
  50. Tratamiento del mieloma múltiple asintomático: recomendaciones del Grupo Español de Mieloma
    María‐Victoria Mateos, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel · 2017 · Medicina Clínica
  51. Fokale Läsionen in der Ganzkörper-MRT beim multiplen Myelom
    Simone Christine Brandelik, Julia Krzykalla, Thomas Hielscher, Jens Hillengaß, Jost Karsten Kloth, Hans‐Ulrich Kauczor, Marc‐André Weber · 2017 · Der Radiologe
  52. Does myeloma genetic have an effect on stem cell mobilization?
    Semih Başçı, Tuğçe Nur Yiğenoğlu, Samet Yaman, Ersin Bozan, Bahar Uncu Ulu, Mehmet Bakırtaş, Ali Kılınç, Nurgül Özcan, Taha Bahsi, Mehmet Sinan Dal et al. · 2021 · Transfusion and Apheresis Science
  53. Smoldering multiple myeloma: biology, clinical manifestations and management
    Laly Nsiala, Arthur Bobin, Anthony Lévy, Cécile Gruchet, Florence Sabirou, Hélène Gardeney, Laura Cailly, Salomon Manier, Niels Moya, Cécile Tomowiak et al. · 2021 · Leukemia & lymphoma/Leukemia and lymphoma
  54. Molecular Diagnostics of Plasma Cell Neoplasms
    Megan J. Fitzpatrick, Mandakolathur R. Murali, Valentina Nardi · 2023 · Surgical pathology clinics
  55. How We Manage Smoldering Multiple Myeloma
    Alessandra Romano, Claudio Cerchione, Concetta Conticello, Giovanni Martinelli, Francesco Di Raimondo · 2020 · Hematology Reports
  56. Treatment of high-risk smoldering myeloma
    Neha Korde · 2016 · Seminars in Oncology
  57. Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease
    Ignacio Isola, David Fernando Moreno, Esther Moga, Mari-Pau Mena, Natalia Tovar, Luis Gerardo Rodríguez‐Lobato, Aina Oliver‐Caldés, M. Carmen Salgado, Fara Brasó‐Maristany, Jordi Yagüe et al. · 2021 · Annals of Hematology
  58. Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression
    Louise Ainley, Marquita Camilleri, Selina J Chavda, Annabel McMillan, Lydia S.H. Lee, Rakesh Popat, Francesca Emily Sillito, Kwee Yong · 2021 · British Journal of Haematology
  59. Creation of a collection of blood samples of patients with multiple myeloma
    Надежда Владимировна Гненная, Софья Владимировна Тимофеева, A. О. Sitkovskaya, Inna Arnoldovna Novikova, Irina B. Lysenko, Камаева Инна Анатольевна, Oleg Ivanovich Kit · 2022 · CARDIOVASCULAR THERAPY AND PREVENTION
  60. Machine Learning Models for Predicting Multiple Myeloma Staging and MGUS Progression Using Gene Expression Data
    Nestoras Karathanasis, George M. Spyrou · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  61. Modeling serum M‐protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone
    Yuki Otani, Yunqi Zhao, Guanyu Wang, Richard Labotka, Mark C. Rogge, Neeraj Gupta, Majid Vakilynejad, Dean C. Bottino, Yusuke Tanigawara · 2024 · CPT Pharmacometrics & Systems Pharmacology
  62. Precursor plasma cell disorders: Classification, risk stratification, and emerging role of early interception
    Tarek H. Mouhieddine, Irene M. Ghobrial, Omar Nadeem · 2025 · Best Practice & Research Clinical Haematology
  63. Predicting chemotherapy toxicity in multiple myeloma: the prognostic value of pre-treatment serum cytokine levels of interleukin-6, interleukin-8, monocyte chemoattractant protein-1, and vascular endothelial growth factor
    Michał Mielnik, Martyna Podgajna, Aneta Szudy‐Szczyrek, Iwona Homa‐Mlak, Radosław Mlak, Aneta Gorący, Marek Hus · 2024 · Frontiers in Immunology
  64. S0120 G.E.M.S.: genomics encounters MGUS and SMM
    Angela A. Dispenzieri · 2014 · Blood
  65. Is it time for preemptive drug treatment of asymptomatic (smoldering) multiple myeloma?
    Adewale Alade Fawole, Rafat Abonour, Michael Stender, Seerin Viviane Shatavi, Susanna S. Gaikazian, Joseph Anderson, Ishmael A. Jaiyesimi · 2014 · Leukemia & lymphoma/Leukemia and lymphoma
  66. Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'
    Arjun Lakshman, Praful Kumar Ravi, S. Vincent Rajkumar, Shaji Kunnathu Kumar · 2018 · Leukemia
  67. Molecular basis of multiple myeloma
    Sabina Ševčı́ková, Dorota Nižňanská, Monika Vlachová, Jana Gregorobá, Jana Kotašková, Marie Jarošová · 2024 · Klinicka onkologie
  68. Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions
    Valeria Ferla, Francesca Farina, Tommaso Perini, Magda Marcatti, Fabio Ciceri · 2024 · Pharmaceuticals
  69. Smoldering multiple myeloma: advances in diagnosis and risk stratification, and evolving therapeutic strategies
    Taku Kikuchi · 2025 · International Journal of Hematology
  70. To treat or not to treat: a state-of-the-art overview of smoldering multiple myeloma
    Ayushi Garg, Srinivas S. Devarakonda · 2026 · Frontiers in Hematology
  71. Early intervention for high-risk smoldering multiple myeloma (SMM)
    Po‐Huang Chen, Hong‐Jie Jhou, Ching‐Liang Ho, Hai-Lun Huang, CHO-Hao Lee · 2026 · Cochrane Database of Systematic Reviews
  72. Conventional and Molecular Cytogenetics in Plasma Cell Neoplasms
    Michelle Dolan · 2015 · Springer eBooks
  73. Tailoring treatment in myeloma: are there clues from biology?
    Niklas Zojer, Heinz Ludwig · 2015 · memo - Magazine of European Medical Oncology
  74. Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients
    Michael Fillitz, Adelheid Seebacher, Michael Panny · 2015 · memo - Magazine of European Medical Oncology
  75. Risk Stratification in Newly Diagnosed Smoldering Multiple Myeloma
    María‐Victoria Mateos, Jesús F. San Miguel · 2017 · Springer eBooks
  76. Epigenetic Modifications in Myeloma: Focused Review of Current Data and Potential Therapeutic Applications
    Suvir Singh, Kunal Jain, Rintu Sharma, Jagdeep Singh, Davinder Paul · 2021 · Indian Journal of Medical and Paediatric Oncology
  77. Applications of noncoding ribonucleic acids in multiple myeloma patients
    Simone Zocchi, Antoine David, Michèle Goodhardt, David Garrick · 2022 · Elsevier eBooks
  78. What Is Genomic High-Risk Myeloma?
    Faith E. Davies, Brian A. Walker · 2022 · Hemato
  79. Role of Conventional Cytogenetics and FISH in the Laboratory Work Up of Plasma Cell Dyscrasias
    Aaishwarya Dhabe, Samipa Das, Mayur Parihar · 2023 · Indian Journal of Medical and Paediatric Oncology
  80. Hematologic Cancers
    Gayanè Aghakhanyan, Martina Sollini, Sara Galimberti, Roberta Zanca, C Bachi, Francesco Bartoli, Paola Anna Erba · 2023 · Springer eBooks
  81. Descriptive analysis of multiple myeloma patients in a real-world setting from the Finnish Hematology Registry
    Giorgi Tskhvarashvili · 2024 · International Journal of Clinical and Experimental Medicine
  82. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact
    Chutima Kunacheewa, Elisabet Esteve Manasanch · 2021 · Expert Review of Hematology
  83. Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
    Yuki Fujimoto, Shikiko Ueno, Kazutaka Oda, Nao Gunda, Yumi Shimomura, Yuka Nishimura, Ayami Yamaguchi, Akari Kuwano, Yuki Ito, Yusuke Baba et al. · 2021 · Cancers
  84. Diagnostic Applications of Nuclear Medicine: Multiple Myeloma
    Martina Sollini, Sara Galimberti, Roberto Boni, Paola Anna Erba · 2017 · Springer eBooks
  85. Treatment of smoldering multiple myeloma
    Alessandro Gozzetti, Marzia Defina, Monica Bocchia · 2013 · Nature Reviews Clinical Oncology
  86. Challenges and Promises of Genetic Stratification of Risk in Multiple Myeloma
    Hara Prasad Pati, Prashant Sharma · 2017 · Indian Journal of Hematology and Blood Transfusion
  87. IMPROVING PRECISION IN THERAPIES FOR HEMATOLOGICAL MALIGNANCIES
    Muntasir Mamun Majumder · 2018 · Työväentutkimus Vuosikirja
  88. Management of asymptomatic myeloma patients
    María‐Victoria Mateos · 2014 · Expert Review of Hematology
  89. Asymptomatic (Smoldering) Myeloma: Treatment Strategy
    María‐Victoria Mateos, Jesús F. San Miguel · 2013 · International Journal of Hematologic Oncology
  90. Lenalidomid und Dexamethason
    Miriam Ahlborn · 2013 · Der Onkologe
  91. Smoldering Multiple Myeloma: Changing the Management Paradigm or Just the Definition ?
    Rafael Ríos Tamayo · 2014 · Journal of Leukemia
  92. Cytogenetics of Plasma Cell Neoplasms
    Jeffrey R. Sawyer · 2016 · Springer eBooks
  93. R-ISS and NLR-ISS can Predict Time to Treatment in Smoldering Myeloma
    Alessandra Romano, Marzia L Consoli, Giuseppe Auteri · 2016 · Journal of Clinical Trials
  94. Clinical Applications of Nuclear Medicine: Multiple Myeloma
    Martina Sollini, Sara Galimberti, Roberto Boni, Paola Anna Erba · 2016 · Springer eBooks
  95. Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group
    María‐Victoria Mateos, Joan Bladé, Juan José Lahuerta, Jesús F. San Miguel · 2017 · Medicina Clínica (English Edition)
  96. Diagnostic Applications of Nuclear Medicine: Multiple Myeloma
    Martina Sollini, Sara Galimberti, Roberto Boni, Paola Anna Erba · 2017 · Springer eBooks
  97. Personalizing MM Treatment: Gaps in Current Knowledge
    Shaji Kunnathu Kumar · 2017 · Springer eBooks
  98. An Investigation of 53BP1 in Multiple Myeloma
    Justin Simms · 2017 · Libraries and Cultural Resources (University of Calgary)
  99. Redefining Smoldering Myeloma
    Amr ElGhammaz · 2016 · Egyptian Journal of Hematology and Bone Marrow Transplantation
  100. Therapeutic Targets and Signaling Pathways for Diagnosis of Myeloma
    Zeeshan Ansar Ahmed, Ashgar Nasir, Muhammad Shariq Shaikh, Tariq Moatter, Afshan Asghar Rasheed · 2019 · IntechOpen eBooks